Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin
- 17 September 2014
- journal article
- research article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 62 (2), 294-302
- https://doi.org/10.1016/j.jhep.2014.09.013
Abstract
No abstract availableKeywords
Funding Information
- F. Hoffmann-La Roche
This publication has 25 references indexed in Scilit:
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV InfectionNew England Journal of Medicine, 2014
- Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 InfectionGastroenterology, 2013
- JUMP-C: A randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patientsHepatology, 2013
- PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patientsHepatology, 2013
- Resistance to Mericitabine, a Nucleoside Analogue Inhibitor of HCV Rna-Dependent RNA PolymeraseAntiviral Therapy, 2012
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1New England Journal of Medicine, 2012
- Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patientsJournal of Hepatology, 2011
- Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191)Hepatology, 2011
- RG7128 Alone or in Combination with Pegylated Interferon??2a and Ribavirin Prevents Hepatitis C Virus (HCV) Replication and Selection of Resistant Variants in HCV?Infected PatientsThe Journal of Infectious Diseases, 2010
- Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative BehaviorBiochemistry, 2009